CG
NGM

Column Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Column Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,136,735
Closed -$28.8M – 7
2024
Q1 		$28.8M Hold
18,136,735
– – 17.96% 3
2023
Q4 		$15.6M Hold
18,136,735
– – 10.29% 4
2023
Q3 		$19.4M Hold
18,136,735
– – 12.89% 5
2023
Q2 		$47M Hold
18,136,735
– – 18.23% 4
2023
Q1 		$74M Hold
18,136,735
– – 26.76% 2
2022
Q4 		$91M Hold
18,136,735
– – 30.31% 2
2022
Q3 		$237M Hold
18,136,735
– – 52.51% 1
2022
Q2 		$233M Buy
18,136,735
+1,890,918
+12% +$26.2M 49.49% 1
2022
Q1 		$248M Buy
16,245,817
+849,701
+6% +$13.3M 45.93% 1
2021
Q4 		$273M Hold
15,396,116
– – 37.08% 1
2021
Q3 		$324M Hold
15,396,116
– – 36.81% 1
2021
Q2 		$304M Hold
15,396,116
– – 42.97% 1
2021
Q1 		$448M Hold
15,396,116
– – 42.88% 1
2020
Q4 		$467M Buy
+15,396,116
New +$337M 42.31% 1

Column Group's NGM Position: Q2 2024 in Review

Column Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 18,136,735 shares — an estimated $28.8M sold.

Column Group first reported a position in NGM in Q4 2020 and held it in 14 quarters. The position peaked at $467M in Q4 2020. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Column Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Column Group sold 18,136,735 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $28.8M.
  • Column Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Column Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $467M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Column Group's 13F filing for Q2 2024, filed 15 Aug 2024.